Abstracts Archive - Page 1020 of 2425 - ACR Meeting Abstracts

Abstract Number: 229 • 2018 ACR/ARHP Annual Meeting
Disability Status, Mortality, and Leading Causes of Death in Seropositive Rheumatoid Arthritis Patients: A Population-Based Study in Korea
In Ah Choi¹, Jeong Seok Lee^2,3 and Eun Young Lee², ¹Division of Rheumatology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ³Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea, Republic of (South)
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to functional disability and premature mortality. We aimed to identify the status of disability…
Abstract Number: 230 • 2018 ACR/ARHP Annual Meeting
Increased Prevalence of Coronary Artery Disease in Patients with Chest Pain and Seropositive Rheumatoid Arthritis: An Analysis from a Clinical Computed Tomography-Based Large-Scale Population Cohort
Andreas Bugge Tingaard¹, Annette de Thurah², Ina Trolle Andersen³, Anders Hammerich Riis³, Josephine Therkildsen⁴, Ellen-Margrethe Hauge⁵ and Morten Böttcher⁴, ¹Department of Cardiology, Regional Hospital of Herning, Herning, Denmark, ²Department of Rheumatology,, Aarhus University Hospital, Nørrebrogade 44, 8000 Aarhus, Denmark, ³Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, ⁴Cardiology, Regional Hospital of Herning, Herning, Denmark, ⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Aarhus, Denmark
Background/Purpose: Inflammation seems to play a central role in the development of atherosclerosis and inflammatory diseases seem to promote progression of coronary artery disease (CAD).…
Abstract Number: 231 • 2018 ACR/ARHP Annual Meeting
Rates of Influenza Vaccination in a Cohort of Patients with Rheumatoid Arthritis and Psoriatic Arthritis
Andreea Coca¹, James Dolan² and Christopher T. Ritchlin², ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester, Rochester, NY
Background/Purpose: The infections complicating rheumatic diseases cause significant morbidity and mortality. Rheumatoid arthritis and psoriatic arthritis patients are at increased risk of infection due to…
Abstract Number: 232 • 2018 ACR/ARHP Annual Meeting
Inpatient Mortality in Transition-Aged Youth with Rheumatic Disease: An Analysis of the National Inpatient Sample
Paul T. Jensen^1,2,3, Keumseok Koh², Rebecca Cash², Stacy P. Ardoin⁴ and Ayaz Hyder², ¹Pediatrics, Nationwide Children's Hospital, Columbus, OH, ²The Ohio State University College of Public Health, Columbus, OH, ³Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Transition from pediatric to adult care is seen as a vulnerable time for youth with chronic diseases. In patients with rheumatic disease, studies show…
Abstract Number: 233 • 2018 ACR/ARHP Annual Meeting
TNF Inhibitors: Prevalence of Use and Predictors of Treatment Non-Persistence in the 2011-2016 Medicare Population
Nicholas S. Roetker, Yi Peng, Kimberly M. Nieman, Suying Li and David T. Gilbertson, Minneapolis Medical Research Foundation, Chronic Disease Research Group, Minneapolis, MN
Background/Purpose: Use of tumor necrosis factor inhibitor (TNFi) drugs is common among patients with rheumatic disease who do not respond to conventional therapies. The aims…
Abstract Number: 234 • 2018 ACR/ARHP Annual Meeting
Population-Based Estimates of Fatigue Prevalence Among Adults Aged >18 Years with and without Arthritis, United States, 2015-2016
Jennifer M. Hootman¹, Louise Murphy¹, Michael Boring¹ and Dana Guglielmo², ¹Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ²Oak Ridge Institute for Science and Education, Oak Ridge, TN
Background/Purpose: Fatigue is a common symptom among adults with arthritis and can severely impact quality-of life. This study’s two objectives were to estimate the national…
Abstract Number: 235 • 2018 ACR/ARHP Annual Meeting
Clinical Predictors and Risk of Methotrexate Induced Liver Fibrosis
Sarah Oberholtzer¹ and Lawrence Worobetz², ¹Department of Internal Medicine, University of Saskatchewan, Saskatoon, SK, Canada, ²Department of Internal Medicine, University of Saskatchewan Division of Gastroenterology, Saskatoon, SK, Canada
Background/Purpose: Methotrexate (MTX) is a highly effective therapy for patients with rheumatologic and dermatologic conditions. Its use infers significant reduction in morbidity and mortality; however,…
Abstract Number: 236 • 2018 ACR/ARHP Annual Meeting
Hypogammaglobulinemia and Infection Risk in Patients Treated with Rituximab
Joana Caetano¹, Frederico Batista¹ and Jose Delgado Alves^2,3, ¹Department of Medicine IV, Systemic Immunomediated Diseases Unit, Fernando Fonseca Hospital, Amadora, Portugal, ²CEDOC/NOVA Medical School, Lisbon, Portugal, ³Department of Medicina IV, Systemic Immunomediated Diseases Unit, Fernando Fonseca Hospital, Amadora, Portugal
Background/Purpose: Rituximab (RTX) is an effective immunosuppressive therapy for many autoimmune diseases. Secondary hypogammaglobulinemia (hypoIg) can occur mainly after repeated cycles of RTX. The risk…
Abstract Number: 237 • 2018 ACR/ARHP Annual Meeting
The Risk of Serious and Opportunistic Infections in Rheumatologic Patients on Interleukin Inhibitors: A Systematic Review and Meta-Analysis
Adam Berlinberg¹, Jawad Bilal², Abdullah Alhifany³, Warda Faridi⁴ and C. Kent Kwoh⁵, ¹Department of Internal Medicine, University of Arizona, Tucson, AZ, ²Internal Medicine, University of Arizona, Tucson, AZ, ³Department of Pharmacy, University of Arizona, Tucson, AZ, ⁴Department of Hematology/Oncology, University of Arizona, Tucson, AZ, ⁵Medicine, Division of Rheumatology, University of Arizona School of Medicine, University of Arizona Arthritis Center, Tucson, AZ
Background/Purpose: Interleukin (IL) inhibitors are increasingly being used for rheumatologic diseases. There are many controlled clinical trials assessing the efficacy of IL inhibitors, but there…
Abstract Number: 238 • 2018 ACR/ARHP Annual Meeting
IL Inhibitors Therapy in Rheumatic Diseases and the Risk of Malignancies: Systematic Review and Meta-Analysis of Rare Harmful Effects in Randomized Controlled Trials
Jawad Bilal¹, Irbaz Bin Riaz², Adam Berlinberg³, Abdullah Alhifany⁴, Gilbert Ortega⁵ and Warda Faridi⁶, ¹University of Arizona, Tucson, AZ, ²Mayo Clinic, Richestor, MN, ³Department of Internal Medicine, University of Arizona, Tucson, AZ, ⁴Department of Pharmacy, University of Arizona, Tucson, AZ, ⁵Internal Medicine, University of Arizona, Tucson, Tucson, AZ, ⁶Department of Hematology/Oncology, University of Arizona, Tucson, AZ
Background/Purpose: Tumor necrosis factor alpha (TNFα) inhibitor therapy in patients with rheumatologic disorders is well known to increase the risk of malignancy. While the individual…
Abstract Number: 239 • 2018 ACR/ARHP Annual Meeting
Outcomes of Hospitalizations and the Temporal Trends in Mortality from Acute Myocardial Infarction in Patients with RA and FM during 2005 to 2015
Atefeh Vafa¹, Setri Fugar² and John P. Case^3,4, ¹Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ²Cardiology, Rush University Medical Center, Chicago, IL, ³Internal Medicine/Rheumatology, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ⁴Internal Medicine, Chicago Medical School, North Chicago, IL
Background/Purpose: RA is associated with an increased risk of coronary artery disease (CAD). This association is believed to be due to systemic inflammation and its…
Abstract Number: 240 • 2018 ACR/ARHP Annual Meeting
Bi-Directional Associations between “Too Much Sitting” and Self-Reported Pain in Patients with Rheumatoid Arthritis
Ciara O'Brien¹, Joan L. Duda¹, Jet J.C.S. Veldhuijzen van Zanten^1,2, George S. Metsios^2,3, George D. Kitas^1,2,4 and Sally A.M. Fenton^1,2, ¹School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, United Kingdom, ²Department of Rheumatology, Russells Hall Hospital, Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom, ³Faculty of Education Health & Wellbeing, University of Wolverhampton, Walsall, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom
Background/Purpose: Epidemiological evidence indicates that sedentary behaviour, or “too much sitting”, is associated with poor health outcomes in the general population, including elevated systemic inflammation.…
Abstract Number: 241 • 2018 ACR/ARHP Annual Meeting
Is There a Relationship between Takotsubo Cardiomyopathy and Fibromyalgia? Insights from the National Inpatient Sample Database
Atefeh Vafa¹, Setri Fugar², Chimezie Mbachi¹, Alexis K Okoh³ and John P. Case⁴, ¹Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ²Cardiology, Rush University Medical Center, Chicago, IL, ³Cardiothoracic surgery, RWJ Barnabas health, Newark beth israel medical center, Newark, NJ, ⁴Internal Medicine, Chicago Medical School, North Chicago, IL
Background/Purpose: Takotsubo cardiomyopathy (TCM) or stress cardiomyopathy is an unusual but potentially fatal type of acute cardiomyopathy characterized by transient regional left ventricular systolic dysfunction.…
Abstract Number: 242 • 2018 ACR/ARHP Annual Meeting
DHEA Deficiency in Fibromyalgia
Thomas Romano, Private Practice, Martins Ferry, OH
Background/Purpose: Fibromyalgia (FM) is a common condition but often difficult to treat. This may be because co-morbidities are unrecognized and pose an impediment to a…
Abstract Number: 243 • 2018 ACR/ARHP Annual Meeting
High Prevalence of Fibromyalgia Among Israel School Teachers
Yaffa Buskila¹, Dan Buskila², Giris Jacob³, Itzhak Weiss⁴ and Jacob N. Ablin^5,6, ¹Orot Israel College of Education, Rehovot, Israel, ²Ben Gurion University and Soroka Medical Center, Beer Sheva, Israel, ³Internal medicine F, Tel Aviv Sourasky medical center, Zichron Yakov, Israel, ⁴School of Education, Bar Ilan University, Ramat Gan, Israel, ⁵Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁶Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Background/Purpose: Fibromyalgia Syndrome (FMS), characterized by widespread pain and fatigue, has frequently been associated with stress in various models, including workplace related stress. In the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].